Scientists test RSV shot in most vulnerable elderly
⭐️ VACCINE ⭐️
Recruiting now
This study is testing how well the approved RSV vaccine Arexvy works in adults aged 80 and older compared to those aged 60-65. Researchers want to see if the vaccine produces a strong immune response in the most elderly and frail populations, who are at highest risk for severe RS…
Phase: PHASE3 • Sponsor: Karin Karin Loré • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 01, 2026 14:41 UTC